| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5899233 | Diabetes Research and Clinical Practice | 2015 | 19 Pages |
Abstract
Patients treated with either gliclazide or DPP-4 inhibitors while fasting during Ramadan have similarly low risks of experiencing symptomatic hypoglycemia. Gliclazide is an effective oral antidiabetic that may be suitable for the management of patients with type 2 diabetes during Ramadan. Individualized Ramadan-focused advice and evening intake of treatment may improve the management of patients with diabetes during Ramadan.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Jean Claude Mbanya, Saud Al-Sifri, Aly Abdel-Rahim, Ilhan Satman,